Related Experiment Video

Updated: Jul 17, 2025

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

4.9K

All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results - Authors'

Hartmut Döhner1, Axel Benner2, Arnold Ganser3

  • 1Department of Internal Medicine III, Ulm University Hospital, Ulm 89081, Germany.

The Lancet. Haematology
|August 31, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

2.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K